Dr. Reddy's Laboratories Q2 FY2026 Financial Results

Dr. Reddy's Laboratories announced its consolidated financial results for the quarter and six months ended September 30, 2025. The company reported revenues of ₹88,051 million for Q2 FY2026, a 9.8% year-over-year (YoY) increase, and ₹173,503 million for H1 FY2026, a 10.6% YoY increase. Gross margin for Q2 FY2026 stood at 54.7%, down from 59.6% in Q2 FY2025. EBITDA for Q2 FY2026 was ₹23,511 million, representing 26.7% of revenues. Profit before tax (PBT) for Q2 FY2026 was ₹18,350 million, a 4% decline YoY. Profit after tax attributable to equity holders was ₹14,372 million, a 14% increase YoY. The company highlighted growth in branded markets and contributions from the Nicotine Replacement Therapy (NRT) portfolio, which offset declines in U.S. Lenalidomide sales. Key business developments included the acquisition of the STUGERON portfolio and the launch of several new products across various markets.